0C0 Stock Chart & Stats
€0.21
<€0.01(1.94%)
At close: 4:00 PM EDT
€0.21
<€0.01(1.94%)
Day’s Range― - ―
52-Week Range€0.16 - €0.58
Previous CloseN/A
Volume0.00
Average Volume (3M)1.45K
Market Cap
€12.45M
Enterprise Value€32.96
Total Cash (Recent Filing)€419.58K
Total Debt (Recent Filing)€553.41K
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding62,959,820
10 Day Avg. Volume1,312
30 Day Avg. Volume1,447
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)39.49
Price to Sales (P/S)4.13
P/FCF Ratio-5.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)€15.68M
Bulls Say, Bears Say
Bulls Say
Licensing-focused Business ModelA licensing-and-royalty model lets MustGrow leverage partners' manufacturing, registration, and distribution capabilities, lowering the firm's capital and operational burden. Over months this supports scalable revenue upside tied to partner sales and milestones without building a large sales infrastructure.
Manageable LeverageReported debt-to-equity near 0.67 indicates leverage is moderate rather than extreme. This profile preserves some financial flexibility to fund regulatory and field programs or bridge financing needs, reducing immediate solvency pressure if cash burn is addressed or financed responsibly.
Exposure To Structural Ag-biologics TrendMustGrow's focus on plant-derived biologics aligns with long-term regulatory and market shifts toward sustainable alternatives and complements to synthetic pesticides. Structural demand for environmentally friendly crop inputs can expand addressable market and partner interest over the medium term.
Bears Say
Persistent Cash BurnSustained negative operating cash flow and deeply negative free cash flow materially reduce runway and force reliance on external financing. Over the coming months this can constrain R&D, regulatory submissions, and commercialization investments and increase dilution or financing costs.
Weak, Volatile Revenue And Deeply Negative MarginsA large TTM revenue decline combined with very negative operating and net margins indicates the business model has not yet produced scalable, profitable sales. This volatility and lack of margin sustainability raises execution risk and hinders ability to fund commercialization organically.
Eroded Equity And Sharply Negative ReturnsA steep decline in shareholder equity and extremely negative ROE reduce the company's loss-absorption capacity and limit strategic flexibility. Over months this weakens balance-sheet resilience, may increase borrowing costs, and raises the risk of dilutive financings or restructuring if performance doesn't improve.
MustGrow Biologics News
0C0 FAQ
What was MustGrow Biologics’s price range in the past 12 months?
MustGrow Biologics lowest stock price was €0.16 and its highest was €0.58 in the past 12 months.
What is MustGrow Biologics’s market cap?
MustGrow Biologics’s market cap is €12.45M.
When is MustGrow Biologics’s upcoming earnings report date?
MustGrow Biologics’s upcoming earnings report date is Aug 20, 2026 which is in 15 days.
How were MustGrow Biologics’s earnings last quarter?
Currently, no data Available
Is MustGrow Biologics overvalued?
According to Wall Street analysts MustGrow Biologics’s price is currently Overvalued.
Does MustGrow Biologics pay dividends?
MustGrow Biologics does not currently pay dividends.
What is MustGrow Biologics’s EPS estimate?
MustGrow Biologics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MustGrow Biologics have?
MustGrow Biologics has 62,959,820 shares outstanding.
What happened to MustGrow Biologics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MustGrow Biologics?
Currently, no hedge funds are holding shares in DE:0C0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MustGrow Biologics
MustGrow Biologics Corp. is an agricultural biotechnology enterprise specializing in the creation and commercialization of natural crop protection solutions. These offerings, including biopesticides, biofumigants, and bioherbicides, are uniquely derived from mustard seed. The company provides a pre-planting soil biofumigation technique aimed at combating soil-borne diseases and pests across diverse agricultural commodities, such as fruits and vegetables. Furthermore, MustGrow is actively developing a bioherbicide to manage undesirable plant growth, intended for use in organic farming, home gardens, and broader agricultural sectors. Their portfolio also extends to post-harvest food preservation, applying treatments to inhibit sprouting, disease, and pathogens, thereby enhancing the shelf life of stored products. A significant offering is CannaPM, an active compound effective against both fungal soil ailments and foliar diseases. Established in 2014 and headquartered in Saskatoon, Canada, the company adopted the name MustGrow Biologics Corp. in March 2018, having previously operated as Duport Capital Ltd.
0C0 Earnings Call
Q1 2026
0:00 / 0:00
Technical Analysis
Progressive Planet Solutions Inc
―
Bee Vectoring Technologies International
―
Gensource Potash
―
Verde Agritech
―
Nutrien
―